Usinumab, or ursinumab injection, Crohn’s, or Crohn’s disease, and ursinumab injection for Crohn’s disease may come back.
Crohn’s disease is an inflammatory disease of the intestines of unknown cause. Ustekinumab Injection binds to cytokines that participate in chronic inflammation and blocks their inflammatory response. It is used in adult patients with moderately to severely active Crohn’s disease.
Adverse reactions to ursinumab injection can be seen as severe hypersensitivity reactions, upper respiratory tract infections, dizziness, headache, oropharyngeal pain, diarrhea, nausea, vomiting, itching, back pain, myalgia, arthralgia, fatigue, erythema at the site of injection, and pain. The drug is contraindicated in people who are allergic to the product, people with active infections such as active tuberculosis.
Crohn’s disease is a chronic inflammatory granulomatous disease that is prone to recurring episodes that are difficult to cure, so the use of ursodenumab injection for the treatment of this disease may also recur. Crohn’s disease requires standardized treatment under the guidance of a doctor.